BR112012031920A2 - treatment of coagulopathies with hyperfibrinolysis. - Google Patents

treatment of coagulopathies with hyperfibrinolysis.

Info

Publication number
BR112012031920A2
BR112012031920A2 BR112012031920A BR112012031920A BR112012031920A2 BR 112012031920 A2 BR112012031920 A2 BR 112012031920A2 BR 112012031920 A BR112012031920 A BR 112012031920A BR 112012031920 A BR112012031920 A BR 112012031920A BR 112012031920 A2 BR112012031920 A2 BR 112012031920A2
Authority
BR
Brazil
Prior art keywords
hyperfibrinolysis
coagulopathies
treatment
thrombomodulin analogs
hyperibrinolysis
Prior art date
Application number
BR112012031920A
Other languages
Portuguese (pt)
Inventor
Herbert Foley Jonathan
Petersen Karl-Uwe
Ernest Nesheim Michael (Falecido)
Original Assignee
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/003541 external-priority patent/WO2010142461A2/en
Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh
Publication of BR112012031920A2 publication Critical patent/BR112012031920A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin

Abstract

tratamento de coagulopatias com hiperfibrinólise - a presente invenção refere-se ao uso de análogos de trombomodulina para a fabricação de um medicamento para tratamento de coagulopatia com hiperibrinólise, tais como distúrbios hemofílicos. esses análogos de trombomodulina exibem em dosagens terapeuticamente eficazes um efeito antifibrinolítico. novas modificações de proteína junto com métodos para sua identificação estão descritos.Treatment of Coagulopathies with Hyperfibrinolysis - The present invention relates to the use of thrombomodulin analogs for the manufacture of a medicament for treating hyperibrinolysis coagulopathy, such as hemophilia disorders. such thrombomodulin analogs exhibit in therapeutically effective dosages an antifibrinolytic effect. Further protein modifications along with methods for their identification are described.

BR112012031920A 2010-06-14 2010-12-15 treatment of coagulopathies with hyperfibrinolysis. BR112012031920A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2010/003541 WO2010142461A2 (en) 2009-06-12 2010-06-14 Treatment of coagulopathy with hyperfibrinolysis
PCT/EP2010/007632 WO2011157283A1 (en) 2010-06-14 2010-12-15 Treatment of coagulopathy with hyperfibrinolysis

Publications (1)

Publication Number Publication Date
BR112012031920A2 true BR112012031920A2 (en) 2017-05-16

Family

ID=43857859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012031920A BR112012031920A2 (en) 2010-06-14 2010-12-15 treatment of coagulopathies with hyperfibrinolysis.

Country Status (6)

Country Link
JP (1) JP2013531651A (en)
CN (1) CN103037893A (en)
AU (1) AU2010355558A1 (en)
BR (1) BR112012031920A2 (en)
CA (1) CA2802072A1 (en)
WO (1) WO2011157283A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038305T2 (en) 2010-11-17 2018-10-29 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
TW201625299A (en) * 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
WO2018047813A1 (en) 2016-09-06 2018-03-15 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
CN107083357B (en) * 2017-06-16 2021-04-02 四川农业大学 Method for inducing and culturing mesenchymal stem cells
JP2019031486A (en) * 2017-08-04 2019-02-28 公立大学法人福島県立医科大学 Novel polypeptide and application thereof
CN107677834B (en) * 2017-09-25 2019-07-09 辽宁迈迪生物科技股份有限公司 The application of the detection method of TAFIa content, the kit for detecting TAFIa content and the two
CN111961137B (en) * 2020-08-27 2023-09-05 南开大学 Fusion protein with bionic endothelial cell function and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE180496T1 (en) 1987-01-08 1999-06-15 Asahi Chemical Ind PEPTIDE TO ACCELERATE THE ACTION OF PROTEIN-C WITH THROMBIN
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
AU8723391A (en) 1990-08-15 1992-03-17 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
WO1993015755A1 (en) 1992-02-05 1993-08-19 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
WO1993025675A1 (en) * 1992-06-10 1993-12-23 Schering Aktiengesellschaft Mutants of the epidermal growth factor domains of human thrombomodulin
WO2002099098A1 (en) 2001-04-04 2002-12-12 American Diagnostica, Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
EP2104508A2 (en) * 2006-12-12 2009-09-30 Eli Lilly And Company Treating acute renal failure with soluble thrombomodulin variants
US20120270789A1 (en) * 2009-06-12 2012-10-25 Paion Deutschland Gmbh Treatment of coagulopathy with hyperfibrinolysis

Also Published As

Publication number Publication date
AU2010355558A1 (en) 2013-01-24
CA2802072A1 (en) 2011-12-22
WO2011157283A1 (en) 2011-12-22
CN103037893A (en) 2013-04-10
JP2013531651A (en) 2013-08-08

Similar Documents

Publication Publication Date Title
BR112012031920A2 (en) treatment of coagulopathies with hyperfibrinolysis.
BR112013027774A2 (en) new compounds as protein kinase modulators
ECSP14013224A (en) SUBSTITUTED RINGED PYRIMIDINES AND USE OF THE SAME
CY1121368T1 (en) ANTI-ASIC1 ANTIBODIES AND THEIR USES
ECSP14013153A (en) METALOENZYM INHIBITING COMPOUNDS
ECSP14013159A (en) METALOENZYM INHIBITING COMPOUNDS
BR112012029904A2 (en) polypeptide purification methods
UY33627A (en) COMPOUNDS TO TREAT NEURODEGENERATIVE DISEASES
BR112015019995A2 (en) THERAPEUTIC COMBINATION INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR THE TREATMENT OF CANCER
CR20140020A (en) METALOENZYM INHIBITING COMPOUNDS
ECSP13012448A (en) NEW AMINOPIRAZOLOQUINAZOLINAS.
EA201690881A1 (en) COMPOUNDS INHIBITORS AUTOTAXIN
EA201291034A1 (en) APTAMERS TO β-NGF AND THEIR APPLICATION IN THE TREATMENT OF B-NGF-MEDIATED DISEASES AND DISORDERS
BR112013033182A2 (en) substituted imidazopyridinyl aminopyridine compounds
GEP20186928B (en) Binding molecules for bcma and cd3
BR112015022156A2 (en) compositions and methods for modulating tau expression
BR112015016395A2 (en) 3-substituted pyrazoles and use as dlk inhibitors
CY1120008T1 (en) BENZAMIDES
EA201300137A1 (en) COMBINED PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OR CONDITIONS ASSOCIATED WITH NEURODEGENERATIVE DISEASES
EA201390704A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
BR112015000443A2 (en) 3-substituted estra-1,3,5 (10), 16-tetraene derivatives, process for their manufacture, pharmaceutical preparations containing them, as well as their use for the production of medicaments
BR112014027981A2 (en) fumagilol type compounds and methods of production and use thereof
BR112016001645A2 (en) oxoquinazolinyl butanamide derivatives
BR112015018071A2 (en) estra-1,3,5 (10), 16-tetraene-3-carboxamides
BR112014008616A2 (en) antiviral compounds

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]